Literature DB >> 25605449

Companion diagnostics at the intersection of personalized medicine and healthcare delivery.

Scott A Waldman1, Andre Terzic.   

Abstract

Entities:  

Keywords:  Food and Drug Administration; clinical trials; companion diagnostics; detection; evidenced-based medicine; individualized and targeted therapy; prediction; prognosis; screening

Mesh：

Year:  2015        PMID： 25605449      PMCID： PMC5533276          DOI： 10.2217/bmm.14.99

Source DB:  PubMed          Journal:  Biomark Med        ISSN： 1752-0363            Impact factor:   2.851


× No keyword cloud information.
  14 in total

Review 1.  Regulatory considerations for companion diagnostic devices.

Authors:  Eunice Y Lee; Hsin-Chieh Jennifer Shen
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 2.  Biomarker use is associated with reduced clinical trial failure risk in metastatic melanoma.

Authors:  Daniel A Rubinger; Sarah S Hollmann; Viktoria Serdetchnaia; D Scott Ernst; Jayson L Parker
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

3.  Information hierarchies optimize patient-centered solutions.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2013-01       Impact factor: 6.875

4.  Advancing pharmacometrics and systems pharmacology.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2012-11       Impact factor: 6.875

5.  Translational medicine individualizes healthcare discovery, development and delivery. Foreword.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

6.  Systems-based discovery advances drug development.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2013-04       Impact factor: 6.875

7.  Molecular insights provide the critical path to disease mitigation.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2014-01       Impact factor: 6.875

Review 8.  HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.

Authors:  Pooja P Advani; Jennifer A Crozier; Edith A Perez
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 9.  Getting the best out of thiopurine therapy: thiopurine S-methyltransferase and beyond.

Authors:  Steven Chung Ming Fong; Paul Andrew Blaker; Monica Arenas-Hernandez; Anthony Marin Marinaki; Jeremy David Sanderson
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

Review 10.  Complementary versus companion diagnostics: apples and oranges?

Authors:  Christopher-Paul Milne; Crystal Bryan; Steven Garafalo; Marie McKiernan
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851
View more
  3 in total

1.  Clinical Pharmacology & Therapeutics: Past, Present, and Future.

Authors:  S A Waldman; A Terzic
Journal:  Clin Pharmacol Ther       Date:  2017-03       Impact factor: 6.875

Review 2.  Pharmacogenomic phase transition from personalized medicine to patient-centric customized delivery.

Authors:  Arun Radhakrishnan; Gowthamarajan Kuppusamy; Sivasankaran Ponnusankar; Nikhitha K Shanmukhan
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

Review 3.  Regenerative medicine clinical readiness.

Authors:  Satsuki Yamada; Atta Behfar; Andre Terzic
Journal:  Regen Med       Date:  2021-02-24       Impact factor: 3.806
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.